Cargando…
Use of mesoporous polydopamine nanoparticles as a stable drug-release system alleviates inflammation in knee osteoarthritis
Osteoarthritis drugs are often short-acting; therefore, to enhance their efficacy, long-term, stable-release, drug-delivery systems are urgently needed. Mesoporous polydopamine (MPDA), a natural nanoparticle with excellent biocompatibility and a high loading capacity, synthesized via a self-aggregat...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AIP Publishing LLC
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9033307/ https://www.ncbi.nlm.nih.gov/pubmed/35496642 http://dx.doi.org/10.1063/5.0088447 |
_version_ | 1784692855950802944 |
---|---|
author | Wang, Yun Ge, Weiwen Ma, Zhigui Ji, Guangyu Wang, Mingsong Zhou, Guangdong Wang, Xiansong |
author_facet | Wang, Yun Ge, Weiwen Ma, Zhigui Ji, Guangyu Wang, Mingsong Zhou, Guangdong Wang, Xiansong |
author_sort | Wang, Yun |
collection | PubMed |
description | Osteoarthritis drugs are often short-acting; therefore, to enhance their efficacy, long-term, stable-release, drug-delivery systems are urgently needed. Mesoporous polydopamine (MPDA), a natural nanoparticle with excellent biocompatibility and a high loading capacity, synthesized via a self-aggregation-based method, is frequently used in tumor photothermal therapy. Here, we evaluated its efficiency as a sustained and controlled-release drug carrier and investigated its effectiveness in retarding drug clearance. To this end, we used MPDA as a controlled-release vector to design a drug-loaded microsphere system (RCGD423@MPDA) for osteoarthritis treatment, and thereafter, tested the efficacy of the system in a rat model of osteoarthritis. The results indicated that at an intermediate drug-loading dose, MPDA showed high drug retention. Furthermore, the microsphere system maintained controlled drug release for over 28 days. Our in vitro experiments also showed that drug delivery using this microsphere system inhibited apoptosis-related cartilage degeneration, whereas MPDA-only administration did not show obvious cartilage degradation improvement effect. Results from an in vivo osteoarthritis model also confirmed that drug delivery via this microsphere system inhibited cartilage damage and proteoglycan loss more effectively than the non-vectored drug treatment. These findings suggest that MPDA may be effective as a controlled-release carrier for inhibiting the overall progression of osteoarthritis. Moreover, they provide insights into the selection of drug-clearance retarding vectors, highlighting the applicability of MPDA in this regard. |
format | Online Article Text |
id | pubmed-9033307 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | AIP Publishing LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-90333072022-04-29 Use of mesoporous polydopamine nanoparticles as a stable drug-release system alleviates inflammation in knee osteoarthritis Wang, Yun Ge, Weiwen Ma, Zhigui Ji, Guangyu Wang, Mingsong Zhou, Guangdong Wang, Xiansong APL Bioeng Articles Osteoarthritis drugs are often short-acting; therefore, to enhance their efficacy, long-term, stable-release, drug-delivery systems are urgently needed. Mesoporous polydopamine (MPDA), a natural nanoparticle with excellent biocompatibility and a high loading capacity, synthesized via a self-aggregation-based method, is frequently used in tumor photothermal therapy. Here, we evaluated its efficiency as a sustained and controlled-release drug carrier and investigated its effectiveness in retarding drug clearance. To this end, we used MPDA as a controlled-release vector to design a drug-loaded microsphere system (RCGD423@MPDA) for osteoarthritis treatment, and thereafter, tested the efficacy of the system in a rat model of osteoarthritis. The results indicated that at an intermediate drug-loading dose, MPDA showed high drug retention. Furthermore, the microsphere system maintained controlled drug release for over 28 days. Our in vitro experiments also showed that drug delivery using this microsphere system inhibited apoptosis-related cartilage degeneration, whereas MPDA-only administration did not show obvious cartilage degradation improvement effect. Results from an in vivo osteoarthritis model also confirmed that drug delivery via this microsphere system inhibited cartilage damage and proteoglycan loss more effectively than the non-vectored drug treatment. These findings suggest that MPDA may be effective as a controlled-release carrier for inhibiting the overall progression of osteoarthritis. Moreover, they provide insights into the selection of drug-clearance retarding vectors, highlighting the applicability of MPDA in this regard. AIP Publishing LLC 2022-04-21 /pmc/articles/PMC9033307/ /pubmed/35496642 http://dx.doi.org/10.1063/5.0088447 Text en © 2022 Author(s). https://creativecommons.org/licenses/by/4.0/All article content, except where otherwise noted, is licensed under a Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ). |
spellingShingle | Articles Wang, Yun Ge, Weiwen Ma, Zhigui Ji, Guangyu Wang, Mingsong Zhou, Guangdong Wang, Xiansong Use of mesoporous polydopamine nanoparticles as a stable drug-release system alleviates inflammation in knee osteoarthritis |
title | Use of mesoporous polydopamine nanoparticles as a stable drug-release system alleviates inflammation in knee osteoarthritis |
title_full | Use of mesoporous polydopamine nanoparticles as a stable drug-release system alleviates inflammation in knee osteoarthritis |
title_fullStr | Use of mesoporous polydopamine nanoparticles as a stable drug-release system alleviates inflammation in knee osteoarthritis |
title_full_unstemmed | Use of mesoporous polydopamine nanoparticles as a stable drug-release system alleviates inflammation in knee osteoarthritis |
title_short | Use of mesoporous polydopamine nanoparticles as a stable drug-release system alleviates inflammation in knee osteoarthritis |
title_sort | use of mesoporous polydopamine nanoparticles as a stable drug-release system alleviates inflammation in knee osteoarthritis |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9033307/ https://www.ncbi.nlm.nih.gov/pubmed/35496642 http://dx.doi.org/10.1063/5.0088447 |
work_keys_str_mv | AT wangyun useofmesoporouspolydopaminenanoparticlesasastabledrugreleasesystemalleviatesinflammationinkneeosteoarthritis AT geweiwen useofmesoporouspolydopaminenanoparticlesasastabledrugreleasesystemalleviatesinflammationinkneeosteoarthritis AT mazhigui useofmesoporouspolydopaminenanoparticlesasastabledrugreleasesystemalleviatesinflammationinkneeosteoarthritis AT jiguangyu useofmesoporouspolydopaminenanoparticlesasastabledrugreleasesystemalleviatesinflammationinkneeosteoarthritis AT wangmingsong useofmesoporouspolydopaminenanoparticlesasastabledrugreleasesystemalleviatesinflammationinkneeosteoarthritis AT zhouguangdong useofmesoporouspolydopaminenanoparticlesasastabledrugreleasesystemalleviatesinflammationinkneeosteoarthritis AT wangxiansong useofmesoporouspolydopaminenanoparticlesasastabledrugreleasesystemalleviatesinflammationinkneeosteoarthritis |